ALFA Finder| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 10.1 | 15.4 | 9.1 |
| Other income | 4.6 | 1.5 | -0.1 |
| Total income | 14.7 | 16.9 | 9.0 |
| Profit before exceptional items & tax | 1.2 | 3.4 | 2.6 |
| Profit before tax | 1.2 | 3.4 | 2.6 |
| Net profit | 0.5 | 3.4 | 2.0 |
| Operating margin | 8.2% | 20.1% | 28.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -75.00% |
|---|---|
| Net profit, quarter on quarter | -85.30% |
| Revenue, year on year | +11.00% |
BSE results filing, BSE: 544445. Figures extracted from the filing.
Asston Pharmaceuticals Ltd: key numbers
- Share price
- ₹155.25
- Market cap
- ₹132.2 Cr
- Revenue (annual)
- ₹25.47 Cr
- Net profit (annual)
- ₹3.87 Cr
- P/E (TTM)
- 34.2×Sector 43.8×
- Promoter holding
- 39.48%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Asston Pharmaceuticals Ltd
All →Asston Pharmaceuticals Board Meeting Date
Asston Pharmaceuticals schedules a November 12, 2026 board meeting to approve half-year unaudited financial statements. Agenda items are proposed until the meeting is held.
Asston Pharmaceuticals Other Announcement
Asston Pharmaceuticals Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026. It also disclosed a recent preferential allotment of 24.10 lakh equity shares.
Asston Pharmaceuticals Other Announcement
Asston Pharmaceuticals Limited announced a change in the company's registered office address within the same city, effective from 15th October 2026.
Asston Pharmaceuticals Capital Structure Change
The company submitted a revised shareholding pattern following the allotment of 24,10,431 equity shares through a preferential allotment dated September 5, 2026.
Asston Pharmaceuticals Board Meeting Date
Asston Pharmaceuticals Limited has scheduled a board meeting on 13 October 2026 to consider other business matters. The company's trading window remains closed until 17 October 2026.
Asston Pharmaceuticals Other Announcement
Asston Pharmaceuticals Limited has appointed M/s. Panchal S K & Associates as its Statutory Auditor for a five-year term. The appointment is effective from April 1, 2026.
- Execution
- 60 months